RxDoctor Payments Data

Robert Keltner, MD

Pulmonary Disease · New London, CTNPI 1154436483

Payments from drug & device makers

$3,807in general payments, 2019–2025

Across 156 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$992
  • Boehringer Ingelheim$340
  • AbbVie$125
  • Genentech USA, Inc.$121
  • Sanofi-aventis U.S. LLC$113
  • plus $251 from 6 others

What the payments were for

  • Food & beverage$3,69397%
  • Education$1143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,807 in reported general payments places this provider in the 65th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$36,631
Medicare patients
382
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter618$551,584
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$41,615
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr61$36,344
Breo ElliptaFluticasone/Vilanterol60$34,878
Spiriva RespimatTiotropium Bromide30$22,811
SymbicortBudesonide/Formoterol Fumarate81$21,158
Combivent RespimatIpratropium/Albuterol Sulfate18$19,457
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$15,243
Qvar RedihalerBeclomethasone Dipropionate28$14,845
Advair HfaFluticasone Propion/Salmeterol18$10,805
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate42$10,798
Spiriva HandihalerTiotropium Bromide11$10,537
Incruse ElliptaUmeclidinium Bromide15$7,416
Albuterol Sulfate HfaAlbuterol Sulfate335$7,272
Wixela InhubFluticasone Propion/Salmeterol38$6,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$1,866$636,540773 claims
AstraZenecaBreztri Aerosphere, Symbicort$992$62,773121 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$340$57,51178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →